Jin Rong Jie·2026-01-08 02:46Core Viewpoint - Alibaba Health and Beijing Meirsen Pharmaceutical Technology Development Co., Ltd. have formed a strategic partnership to collaborate in the field of innovative drugs for pediatric specialties, specifically focusing on the first approved topical treatment for infantile hemangiomas, Betamethasone® [1][2] Group 1: Product Development and Clinical Data - Betamethasone® is the first topical gel specifically designed for treating infantile hemangiomas, addressing a significant clinical gap in pediatric care [2] - The product underwent twelve years of research and development, culminating in a successful Phase III clinical trial with a clinical cure rate of 60.7% and an overall efficacy rate of 89.4% among 121 infants aged 1-6 months [2] Group 2: Strategic Collaboration and Market Launch - The exclusive launch of Betamethasone® on Alibaba Health's platform is scheduled for January 13, with plans to initiate a "Care Program for Infantile Hemangiomas" that includes expert consultations, educational broadcasts, and community support [3] - The collaboration aims to integrate Alibaba Health's ecosystem capabilities with Meirsen's expertise in pediatric drug development, enhancing health management solutions for children [7]